Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.45 |
| ▸ | GHSR | Q92847 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317870 | 0.89 | TACR1 (0.41) | TACR1GHSROPRM1BDKRB2 | |
| SCHEMBL6317497 | 0.88 | TACR1 (0.41) | TACR1OPRM1BDKRB2MEN1KMT2A | |
| SCHEMBL6319124 | 0.85 | GHSR (0.53) | TACR1GHSROPRM1 | |
| SCHEMBL6319133 | 0.85 | GHSR (0.53) | TACR1GHSROPRM1 | |
| SCHEMBL8905243 | 0.85 | GHSR (0.45) | TACR1GHSROPRM1BDKRB2 | |
| SCHEMBL7060362 | 0.84 | GHSR (0.55) | TACR1GHSROPRM1 | |
| SCHEMBL7060365 | 0.84 | GHSR (0.55) | TACR1GHSROPRM1 | |
| SCHEMBL27506261 | 0.84 | KMT2A (0.50) | OPRM1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7064980 | 0.84 | KMT2A (0.50) | OPRM1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6316485 | 0.81 | GHSR (0.52) | TACR1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | TACR1 241/4885GHSR 2/4885OPRM1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.